Why In Vivo Biological Testing Matters
While in vitro assays prove that liposomes are safe and highly effective at the cellular level, in vivo biological testing provides the ultimate scientific validation by tracking their performance within a complex, living organism. Through in vivo biological evaluation, three definitive milestones are determined: systemic bioavailability & ADME profiling, systemic safety & tolerability and real-world efficacy. By demonstrating the formulation’s behaviour in a complex biological system while delivering health benefits, in vivo evaluation serves as the essential, data-driven bridge required to confidently advance a product into human clinical trials (CT). It is therefore a prerequisite testing and stepping stone towards clinical trials.
In vivo toxicity testing evaluates the safety of liposomal products through acute, sub-acute, and sub-chronic studies in animal models. It establishes key parameters such as LD₅₀, NOAEL, and NOEL in line with OECD guidelines.
PK–PD studies correlate drug concentration with therapeutic response to understand efficacy and dosing behaviour. For liposomal systems, they provide insights into ADME characteristics and controlled release performance.
Biodistribution studies track organ-specific accumulation of liposomal formulations using labelled systems. This helps confirm targeting efficiency and understand distribution across tissues such as liver, spleen, and brain.
LipoEdge performs toxicity studies using validated animal models and standardised OECD protocols to ensure regulatory-grade data. Detailed pathological and histological assessments support accurate safety profiling and submission readiness.
Bioavailability studies measure the extent and rate of absorption compared to conventional formulations. These studies confirm enhanced systemic exposure and targeted delivery advantages of liposomal systems.